Merck & Co., Inc. (MRK) Poised for Breakout After Strategic M&A and Pipeline Expansion

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Merck & Co., Inc. tops our list for being one of the best cancer stocks.

TheFly reported on January 8 that Wolfe Research analyst Alexandria Hammond upgraded MRK to Outperform from Peer Perform with a $135 price target. The firm described the five-year revenue outlook as “attractive” and stated that the stock is “poised for a breakout” after accretive M&A and ahead of a catalyst-rich era after integrating MRK’s late-stage pipeline, possible label expansions, and prescriber feedback into its models.

Separately, on January 9, reports emerged that MRK is in active talks to acquire Revolution Medicines for approximately $30 billion.

Merck & Co., Inc. (NYSE:MRK) is a leading oncology company driven by its blockbuster immunotherapy Keytruda, with a diversified cancer portfolio spanning immuno-oncology, targeted therapies, and combination regimens, supported by an expanding clinical pipeline and strategic acquisitions to sustain long-term growth.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.